Cover Image
市場調查報告書

裘馨氏肌肉萎縮症:開發平台分析

Duchenne Muscular Dystrophy - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232813
出版日期 內容資訊 英文 296 Pages
訂單完成後即時交付
價格
Back to Top
裘馨氏肌肉萎縮症:開發平台分析 Duchenne Muscular Dystrophy - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 296 Pages
簡介

裘馨氏肌肉萎縮症 是引起肌肉無力,鏈接到X染色體的疾病。有這個疾病的遺傳基因在X染色體中,編碼於Dystrophin蛋白。 Dystrophin是在肌肉細胞內支撐組織結構不可或缺的物質。症狀通常在 6歲左右或比其年幼時出現,可觀察到疲勞、學習障礙、知的障礙、肌肉無力、進行性步行困難。

本報告提供裘馨氏肌肉萎縮症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等新聞和發表。

簡介

  • 調查範圍

裘馨氏肌肉萎縮症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Acceleron Pharma, Inc.
  • Anagenesis Biotechnology
  • Asklepios BioPharmaceutical, Inc.
  • Bamboo Therapeutics, Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • Capricor Therapeutics, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • 第一三共
  • Debiopharm International S.A.
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • EryDel SPA
  • FibroGen, Inc.
  • Galapagos NV
  • Genethon
  • GTx, Inc.
  • Idera Pharmaceuticals, Inc.
  • Italfarmaco S.p.A.
  • La Jolla Pharmaceutical Company
  • Marathon Pharmaceuticals, LLC
  • Marina Biotech, Inc.
  • Merck KGaA
  • Milo Biotechnology LLC
  • MyoTherix Inc.
  • NicOx S.A.
  • 日本新藥
  • nLife Therapeutics, S.L.
  • Nobelpharma Co., Ltd.
  • Pfizer Inc.
  • Prothelia, Inc.
  • PTC Therapeutics, Inc.
  • RASRx, LLC
  • ReveraGen BioPharma, Inc.
  • Sanofi
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics, Inc.
  • Summit Therapeutics Plc
  • 大鵬藥品工業
  • WAVE Life Sciences Ltd.
  • Zambon Company S.p.A.

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 4-P001
  • AAV1-Foliistatin
  • ACE-083
  • alisporivir
  • 裘馨氏肌肉萎縮症用Dystrophin活性反義寡核苷酸 1
  • 裘馨氏肌肉萎縮症用Dystrophin活性反義寡核苷酸
  • 裘馨氏型/貝克氏肌肉萎縮症用肌肉生長抑制素抑制反義寡核苷酸
  • 裘馨氏肌肉萎縮症用 ACVR2B抑制反義寡核苷酸
  • 裘馨氏肌肉萎縮症用反義RNAi寡核苷酸
  • 遺傳性疾病、肌肉骨骼障礙用Calcineurin活性核酸適體
  • arbekacin
  • ARM-210
  • AT-300
  • ataluren
  • Biostrophin
  • BMBD-001
  • BMN-044
  • BMN-045
  • BMN-053
  • BMS-986089
  • CAP-1002
  • CAT-1004
  • CAT-1040
  • CAT-1041
  • DA-4210
  • deflazacort
  • dexamethasone sodium phosphate
  • domagrozumab
  • drisapersen
  • 裘馨氏肌肉萎縮症治療藥
  • DS-5141b
  • DT-200
  • enobosarm
  • eteplirsen
  • FG-3019
  • 裘馨氏肌肉萎縮症用遺傳基因療法
  • 裘馨氏型/肢帶型肌萎縮症用Dysferlin活性遺傳基因療法
  • 裘馨氏肌肉萎縮症用Dystrophin活性遺傳基因療法
  • givinostat
  • Gtx-027
  • IB-DMD
  • idebenone
  • IMO-8400
  • LJPC-30Sa
  • LJPC-30Sb
  • MG-53
  • MP-101
  • Myomir
  • naproxcinod
  • NBD Peptide
  • NS-065
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸 1
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸 2
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸 3
  • 缺血性心臟疾病、裘馨氏肌肉萎縮症用寡核苷酸
  • OSX-200
  • poloxamer
  • PRO-052
  • PRO-055
  • PRT-01
  • 肌肉萎縮症用組換蛋白質
  • 肌肉萎縮症用Utrophin活性組換蛋白質
  • 裘馨氏肌肉萎縮症用組換蛋白質
  • rimeporide
  • RTC-13
  • 裘馨氏肌肉萎縮症用小分子
  • 裘馨氏肌肉萎縮症用Dystrophin活性小分子
  • 裘馨氏肌肉萎縮症用小分子
  • 裘馨氏肌肉萎縮症用Utrophin標靶藥物
  • SMT-022357
  • SMTC-1100
  • SRP-4008
  • SRP-4044
  • SRP-4045
  • SRP-4050
  • SRP-4052
  • SRP-4053
  • SRP-4055
  • 裘馨氏肌肉萎縮症用Dystrophin活性幹細胞療法
  • Stryka-516
  • Stryka-969
  • StrykaPro-1
  • 裘馨氏肌肉萎縮症用合成肽
  • tadalafil
  • TAS-205
  • TVN-102
  • TXA-127
  • Verolone
  • ZP-049
  • ■最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9635IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2017, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 12, 11, 2, 53 and 15 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 8 and 1 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Duchenne Muscular Dystrophy - Overview
  • Duchenne Muscular Dystrophy - Therapeutics Development
  • Duchenne Muscular Dystrophy - Therapeutics Assessment
  • Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
  • Duchenne Muscular Dystrophy - Drug Profiles
  • Duchenne Muscular Dystrophy - Dormant Projects
  • Duchenne Muscular Dystrophy - Discontinued Products
  • Duchenne Muscular Dystrophy - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Duchenne Muscular Dystrophy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by 4P-Pharma SAS, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Acceleron Pharma Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Antisense Therapeutics Ltd, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Beech Tree Labs Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Bioleaders Corp, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by BioMarin Pharmaceutical Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by CRISPR Therapeutics, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Debiopharm International SA, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Editas Medicine Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Eloxx Pharmaceuticals Ltd, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by FibroGen Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Genethon SA, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by GTx Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by GW Pharmaceuticals Plc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Italfarmaco SpA, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Karyopharm Therapeutics Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by La Jolla Pharmaceutical Company, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Lexicon Pharmaceuticals Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Marathon Pharmaceuticals LLC, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Marina Biotech Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Merck KGaA, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Mitobridge Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Mitochon Pharmaceuticals Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by N-Gene Research Laboratories Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by NicOx SA, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co Ltd, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Novartis AG, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by NS Pharma Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Pluristem Therapeutics Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Prothelia Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by SOM Biotech SL, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Strykagen Corp, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Summit Therapeutics Plc, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
  • Duchenne Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd, H2 2017
  • Duchenne Muscular Dystrophy - Dormant Projects, H2 2017
  • Duchenne Muscular Dystrophy - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Duchenne Muscular Dystrophy - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Duchenne Muscular Dystrophy - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Duchenne Muscular Dystrophy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top